TwitterLinkedin

Contact Us

  • Biopharma Excellence
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Current Opportunities
  • Training
Top Bar
Search
PharmaLex Logo
MENUMENU
  • PharmaLex Logo
  • PharmaLex Logo
  • About UsAbout Us
    • About Us
    • Management Team
    • Corporate Social Responsibility
    • What Our Clients Say About Us
  • Our Services
    • Discovery / Non-clinical
          • Go to Discovery / Non-clinical section >>

          • Strategy and Consulting

            • Integrated Product Development
            • Market Access
            • Scientific Advice
            • Statistics and Data Sciences
            • Toxicology Services
    • Clinical Development
          • Go to Clinical Development section >>

          • Strategy and Consulting

            • Clinical Program Development
            • Scientific Advice
            • Statistics and Data Sciences
          • Regulatory Affairs

            • Clinical Trial Applications
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Regulatory Operations
          • Pharmacovigilance

            • Clinical Trial Safety Support
            • Pharmacovigilance Consulting
          • Quality

            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
            • Tech Transfer / Scale-up
    • Authorization / Approval
          • Go to Authorization / Approval section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Regulatory Operations
            • Scientific, Regulatory and Technical Writing
            • Statistics and Data Sciences
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • Pharmacovigilance Consulting
          • Quality

            • Commercialization Readiness
            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • PAI Readiness
    • Post-approval / Maintenance
          • Go to Post-approval / Maintenance section >>

          • Strategy and Consulting

            • Market Access
          • Regulatory Affairs

            • CMC Services
            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Health Authority / Agency Interaction
            • Marketing and Labeling Activities
            • Mergers and Acquisitions (M&A) Transfers
            • Regulatory Operations
            • Toxicology Services
          • Pharmacovigilance

            • EU QPPV / National QPPV
            • ICSR (Individual Safety Case Report) Management
            • Literature Monitoring & Screening
            • Pharmacovigilance Quality & Compliance
            • Signal Management
          • Quality

            • Commissioning, Qualification, and Validation (CQV)
            • GxP Services
            • Interim / Contract QA
            • Quality Management Systems
          • Medical Affairs

            • Healthcare Compliance and Medical Approval
    • Program Management
          • Go to Program Management section >>

          • Program Management

            • Global End-to-End Outsourcing
            • Global Procedure Management
            • Integrated Product Development
            • Mergers and Acquisitions (M&A) Transfers
    • Featured Expertise
          • Industry Expertise

            • Biopharmaceuticals
            • MedTech Services
          • Service Expertise

            • ATMP / Cell and Gene Therapy
            • COVID-19 Support
            • GxP Services
            • Market Access
            • Pharmacovigilance Consulting
            • Post-Brexit Regulatory Support
            • Statistics and Data Sciences
            • SMARTPHLEX - technology-enabled services
  • Global ReachGlobal Reach
  • Contact usContact us
  • News & Events
    • Industry News Articles
    • Press Releases
    • Webinars
    • Events
    • Blog
    • Podcasts
  • Resource Library
    • Thought Leadership
    • Fact Flyers
    • Case Studies
    • White Papers
    • Webinars
    • Infographics
    • Video & Animation
  • Careers
    • Life at PharmaLex
    • Career Opportunities
  • Training
Home > News & Events > Blog > Upcoming TGA Deadlines for Medicine Labelling and Product Information Reform

Upcoming TGA Deadlines for Medicine Labelling and Product Information Reform

Author: Reena Patel

2020 was flagged to be a big year for TGA Sponsors of Medicines with two long-standing milestones on the horizon. Whilst there is no doubt this won’t be a year we forget in a hurry; it is timely to remind ourselves of some forthcoming deadlines.

Therapeutic Product Labelling Reform
The 31st of August 2020 marks the end of the medicines packaging reform which commenced in 2016. The intent of the reform was to make Australian medicine labels clearer and more informative for patients and consumers.

What is it and why is it happening?
The TGA introduced updated labelling requirements for medicines supplied in Australia that saw two new labelling orders to replace the existing Therapeutic Goods Order No. 69 – General requirements for labels of medicines (TGO 69):

  • TGO 91 – Standard for labels of prescription and related medicines (TGO91)
  • TGO 92 – Standard for labels of non-prescription medicines (TGO92)

These new labelling orders came into effect 31 August 2016, with a four-year transition period. During the transition period companies could choose to comply with the old labelling requirements under TGO 69 or the new labelling requirements. Sponsors can continue to store and supply medicines that are compliant with TGO 69 if they are released for supply on or before 31 August 2020. However, from 1 September 2020 all medicines released for supply must comply with either TGO 91 or TGO 92.

TGO 91 and TGO 92 are available on the Federal Register of Legislation and the TGA website includes a guidance document to assist companies update the labelling of products to comply with the new requirements.

What types of products are affected?
All therapeutic products registered on the Australian Register of Therapeutic Goods (ARTG) unless exempted in the applicable TGO.

What do I need to do?
If you have therapeutic products within scope, you should review your product labelling to ensure it complies with the applicable updated TGO. If not, you need to submit an application to the TGA to update your product labelling.

Anything else I should consider?
Yes! All medicines released for supply from 1 September 2020 must comply with TGO 91 or 92. Therefore, to ensure continuity of your medicine supply you may wish to confirm you have released sufficient stock for supply on or before 31 August 2020, and you have enough time to implement your revised labelling to avoid any disruption.

Product Information Reformat
Australian Product Information (PI) documents for marketed products will need to be in the TGA’s new format by 31 December 2020, marking the end of a 3-year transition period.

What is it and why is it happening?
The format of Australian Product Information (PI) documents were updated in November 2017. The format was developed in consultation with health professionals and sponsors to ensure critical clinical information was more accessible and structure aligned with the formatting requirements of comparable international regulatory agencies. The updated PI format came into effect on 1 January 2018, and a revised version of the Form for providing Product Information was approved on 8 March 2018. Revisions included updated references to the Therapeutic Goods Act, updates to improve Form clarity and additional instructions.

What types of products are affected?
In Australia, it is a legal requirement to have a PI for all restricted medicines and selected other medicines. Restricted medicines include:

  • Prescription medicines (ie all medicines in Schedules 4 and 8 of the Poisons Standard)
  • Pharmacist only medicines (ie medicines that contain a substance in Schedule 3 of the Poisons Standard)

PI’s can also be requested for other medicines that are being evaluated by the Prescription Medicines Authorisation Branch.

The deadline for implementation only applies to marketed products. PI’s for non-marketed products can remain in the old format, however they will need to be reformatted before the product can be marketed.

What do I need to do?
If your product has a PI, it is still in the old format, and you intend to supply your product from 1 January 2021, you need to submit an application to the TGA to update it. Reformatted PIs can be submitted with any other application type related to that medicine, including minor variations, safety related requests, and applications to update medicine ingredient names. Reformatted PIs submitted with any other application type do not attract an additional fee.

Reformatted PIs can also be submitted as a stand-alone application. Applications should be submitted as a Minor Editorial Change (MEC) through the TGA eBS portal, using the Prescription Medicine Minor Variation e-form. Applications where the only variation proposed is to reformat the PI, with no other editorial changes, will be exempt from fees between 1 January 2020 and 31 December 2020.

Anything else I should consider?
The TGA have recently updated the format requirements for Consumer Medicine Information (CMI) and released a new CMI template, so you might want to take the opportunity to update the CMI at the same time. You can find more information on the CMI reform here.

Contact us
Related posts
Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
2nd June 2022
Medical device software brings new complications around compliance
Medical device software brings new complications around compliance
30th May 2022
Is quality documentation an asset or a burden in regulatory affairs?
Is quality documentation an asset or a burden in regulatory affairs?
6th April 2022
Navigating the impact of the IVDR on marketed products
Navigating the impact of the IVDR on marketed products
24th March 2022
Minimizing risk during the transport of medicinal products
Minimizing risk during the transport of medicinal products
21st March 2022
Next Steps for EUDAMED implementation within MDR
Next Steps for EUDAMED implementation within MDR
7th March 2022
Recent Blogs
  • Sponsors gear up for a smoother process with CTIS but must first overcome key hurdles
    2nd June 2022
  • Medical device software brings new complications around compliance
    30th May 2022
  • Is quality documentation an asset or a burden in regulatory affairs?
    6th April 2022
  • Navigating the impact of the IVDR on marketed products
    24th March 2022
  • Minimizing risk during the transport of medicinal products
    21st March 2022
  • Next Steps for EUDAMED implementation within MDR
    7th March 2022
Recent News
  • Why collaboration and an Integrated Product Development program are key to successful drug development
    14th June 2022
  • Key Takeaways from the PDA Europe Annex 1 Workshop
    7th June 2022
  • Addressing Limitations of Sterility Testing
    9th May 2022
  • Are virtual audits sustainable post-pandemic?
    6th May 2022
  • Orphan Drug Designation: Securing the Significant Benefits
    28th March 2022
  • PharmaLex expands pricing & reimbursement and health economics platform with EBMA Consulting merger
    9th March 2022
Upcoming Webinars

June 30th, 2022

Transforming the drug development process with an integrated strategy

03:00 PM CET

Biopharma Excellence Website Image

PharmaLex Brings You Biopharma Excellence

Biopharma Excellence is a fusion of three scientific powerhouses, PharmaLex, ERA Consulting and Biopharma Excellence – all under the PharmaLex brand. This global team of scientific, regulatory and commercial professionals provide strategic product development and proactive regulatory services to developers of biopharmaceuticals, cell and gene therapies, monoclonal antibodies (MABs), vaccines and biosimilars.

Visit Website
USEFUL LINKS
  • Home
  • Contact us
  • Imprint
  • Data Protection
  • Terms and Conditions
RECENT TWEETS
PharmaLexGLOBALPharmaLex@PharmaLexGLOBAL·
12h

The #CTIS brings many opportunities, but it will also require a lot of process changes and preparation, find out more 👉https://lnkd.in/eZRqyPPX about the benefits and challenges with the CTIS.

➡  Take the @Phlexglobal #survey! https://lnkd.in/eA5FwHJC

COVID-19 NEWSLETTER SIGN UP

SIGN UP NOW

WHAT OUR CLIENTS SAY
  • They are available when we need to talk to them despite any time zone differentials

    Japan based medium sized company
    Manager
PharmaLex
©2022 PharmaLex GmbH. All rights reserved.

ISO9001:2015 LogoEnergie Audit LogoSGS Logo

Suspicious Emails

We are aware of a number of suspicious emails about recruitment in circulation purporting to be from PharmaLex. Emails sent by PharmaLex will originate from @pharmalex.com. Should you receive an email and are unsure as to its validity, please report it to contact@pharmalex.com.

Many thanks for your understanding.

The PharmaLex Team

    Please DO NOT send us event/conference information.
    We will not respond and these will be deleted immediately.






    Select your state:

    .
    If you do not wish to receive any communication from us, you may unsubscribe at any time.

    #AskTheExpert #TogetherBEYONDCOVID19





      Select your state:

      .
      You can unsubscribe at any time at data.protection@pharmalex.com

      If you do not wish to receive any communication from us, you can unsubscribe at any time at. Click here to view our Privacy Policy.

      #TogetherBEYONDCOVID19

      We closely monitor developments and updates surrounding the current outbreak of Coronavirus Disease 2019 (COVID-19) from official sources including the World Health Organisation and are following the guidance and direction of the governments and the local authorities. We are taking this situation very seriously and our number one priority is the safety and business continuity for our customers and colleagues. As ever, we will do everything we can to ensure that services are delivered within the required time and the trusted quality PharmaLex is known for